Table 2. Outcome after post–allo-HCT... | American Society of Hematology

Table 2.

Outcome after post–allo-HCT nivolumab administration

Patient	Transplantation modalities and complications					Nivolumab						Outcome
	Donor type	Conditioning	History of GVHD/type	Localization	Grade	Time from allo-HCT to initiation (mo)	Treatment duration (weeks)	Reason for discontinuation	Nivolumab-induced GVHD			Follow-up (d)*	Current status	Cause of death
	Donor type	Conditioning	History of GVHD/type	Localization	Grade	Time from allo-HCT to initiation (mo)	Treatment duration (weeks)	Reason for discontinuation	Localization	Treatment	Grade	Follow-up (d)*	Current status	Cause of death
1	MUD	Thio-Bu-Flu	Acute/chronic	Skin/ mucosa, mild	II	15	2	Nivolumab-induced GVHD	Liver	Corticosteroids and cyclosporine	III	154	Still in response	NA
2	Double unit-CB	Flu-Cy-TBI	Acute	Skin and gastrointestinal tract	III	9	2	Nivolumab-induced GVHD	Skin	Corticosteroids	I	223	Still in response	NA
3	MRD	Flu-Bu-ATG	Acute	Skin	III	19	2	Nivolumab-induced GVHD	Liver	Corticosteroids	III	105	Died in response	Grade III GVHD and care refusal
4	MRD	Flu-Bu-ATG	Acute	Skin and gastrointestinal tract	II	8	2	Nivolumab-induced GVHD	Skin	Corticosteroids	III	363	Still in response	NA
5	MUD	Flu-TBI-ATG	Acute	Skin	II	2	2	Nivolumab-induced GVHD	Skin and liver	No immunosuppressive therapy	IV	NE	Response not evaluable	Multiple organ failure
6	Haplo (father)	Flu-Cy-TBI	Acute	Skin and gastrointestinal tract	III	7	2	Nivolumab-induced GVHD	Skin	Corticosteroid, basiliximab and photopheresis	IV	132	Death after relapse	Progressive disease
7	MRD	Flu-Bu-ATG	Acute	Skin	II	17	50	Ongoing	No			188	Relapse, new response after re-treatment	NA
8	MUD	Flu-Bu-ATG	Acute	Skin	III	51	33	Relapse	No			245	Relapse	NA
9	MRD	Flu-Bu-ATG	Acute	Skin and gastrointestinal tract	II	27	34	Ongoing	No			231	Still in response	NA
10	MRD	Flu-Mel	Acute	Skin	I	59	67	Ongoing	No			450	Still in response	NA
11	Double-unit CB	Flu-Cy-TBI	Chronic	Skin	NA	29	13	Consolidation with a second allo-HCT	No			468	Still in response	NA
12	MRD	Flu-TBI	Chronic	Mucosa	NA	105	67	Ongoing	No			462	Still in response	NA
13	MMUD	Flu-Bu-ATG	Chronic	Skin	NA	7	7	Cerebellar ataxia	No			437	Still in response	NA
14	MMUD	Flu-TBI	No			28	17	Relapse	No			117	Relapse	NA
15	MRD	Flu-Bu-ATG	No			12	14	Relapse	No			98	Relapse	Complications of second allo-HCT
16	MRD	Flu-Bu-ATG	No			27	55	Ongoing	No			365	Still in response	NA
17	Double-unit CB	Flu-Cy-ATG	No			12	55	Ongoing	No			374	Still in response	NA
18	MMUD	Flu-Bu-ATG	No			33	21	Hematologic toxicity	No			456	Still in response	NA
19	MRD	Flu-Bu-ATG	No			111	71	Ongoing	No			486	Still in response	NA
20	MRC	Flu-Bu-ATG	No			53	8	No response	No			56	No response	NA

Patient	Transplantation modalities and complications					Nivolumab						Outcome
	Donor type	Conditioning	History of GVHD/type	Localization	Grade	Time from allo-HCT to initiation (mo)	Treatment duration (weeks)	Reason for discontinuation	Nivolumab-induced GVHD			Follow-up (d)*	Current status	Cause of death
	Donor type	Conditioning	History of GVHD/type	Localization	Grade	Time from allo-HCT to initiation (mo)	Treatment duration (weeks)	Reason for discontinuation	Localization	Treatment	Grade	Follow-up (d)*	Current status	Cause of death
1	MUD	Thio-Bu-Flu	Acute/chronic	Skin/ mucosa, mild	II	15	2	Nivolumab-induced GVHD	Liver	Corticosteroids and cyclosporine	III	154	Still in response	NA
2	Double unit-CB	Flu-Cy-TBI	Acute	Skin and gastrointestinal tract	III	9	2	Nivolumab-induced GVHD	Skin	Corticosteroids	I	223	Still in response	NA
3	MRD	Flu-Bu-ATG	Acute	Skin	III	19	2	Nivolumab-induced GVHD	Liver	Corticosteroids	III	105	Died in response	Grade III GVHD and care refusal
4	MRD	Flu-Bu-ATG	Acute	Skin and gastrointestinal tract	II	8	2	Nivolumab-induced GVHD	Skin	Corticosteroids	III	363	Still in response	NA
5	MUD	Flu-TBI-ATG	Acute	Skin	II	2	2	Nivolumab-induced GVHD	Skin and liver	No immunosuppressive therapy	IV	NE	Response not evaluable	Multiple organ failure
6	Haplo (father)	Flu-Cy-TBI	Acute	Skin and gastrointestinal tract	III	7	2	Nivolumab-induced GVHD	Skin	Corticosteroid, basiliximab and photopheresis	IV	132	Death after relapse	Progressive disease
7	MRD	Flu-Bu-ATG	Acute	Skin	II	17	50	Ongoing	No			188	Relapse, new response after re-treatment	NA
8	MUD	Flu-Bu-ATG	Acute	Skin	III	51	33	Relapse	No			245	Relapse	NA
9	MRD	Flu-Bu-ATG	Acute	Skin and gastrointestinal tract	II	27	34	Ongoing	No			231	Still in response	NA
10	MRD	Flu-Mel	Acute	Skin	I	59	67	Ongoing	No			450	Still in response	NA
11	Double-unit CB	Flu-Cy-TBI	Chronic	Skin	NA	29	13	Consolidation with a second allo-HCT	No			468	Still in response	NA
12	MRD	Flu-TBI	Chronic	Mucosa	NA	105	67	Ongoing	No			462	Still in response	NA
13	MMUD	Flu-Bu-ATG	Chronic	Skin	NA	7	7	Cerebellar ataxia	No			437	Still in response	NA
14	MMUD	Flu-TBI	No			28	17	Relapse	No			117	Relapse	NA
15	MRD	Flu-Bu-ATG	No			12	14	Relapse	No			98	Relapse	Complications of second allo-HCT
16	MRD	Flu-Bu-ATG	No			27	55	Ongoing	No			365	Still in response	NA
17	Double-unit CB	Flu-Cy-ATG	No			12	55	Ongoing	No			374	Still in response	NA
18	MMUD	Flu-Bu-ATG	No			33	21	Hematologic toxicity	No			456	Still in response	NA
19	MRD	Flu-Bu-ATG	No			111	71	Ongoing	No			486	Still in response	NA
20	MRC	Flu-Bu-ATG	No			53	8	No response	No			56	No response	NA

ATG, antithymocyte globulin; Bu, busulfan; CB, cord blood; Cy, cyclophosphamide; Flu, fludarabine; Haplo, familial haploidentical donor; Mel, melphalan; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; NA, not applicable; TBI, total body irradiation; Thio, thiotepa.

Follow-up duration is given from nivolumab initiation.

View Large

This Feature Is Available To Subscribers Only